Study rebutting fracture link to Depo queried
US researchers, including Pfizer employees, conducted a retrospective cohort study using a database containing the prescription records of more than 312,000 women using contraceptives alongside information about their fracture incidence.
They found depot medroxyprogesterone acetate (DMPA) users had a 28% higher risk of fracture than non-DMPA users before contraception use started. However, according to the results of the study, fracture risk in DMPA users did not increase after starting DMPA.
“Furthermore, longer-term DMPA users had a lower fracture risk than shorter-term users, which would be unexpected if the higher fracture risk among DMPA users was related to an adverse effect of DMPA on bone,” the authors wrote.
But Dr Sonia Davison, an endocrinologist in private practice at Jean Hailes, Melbourne, was concerned the study results were skewed by the lack of placebo-matched controls.
She was also suspicious of